Zepbound Weight Loss Calculator
Project your expected weight loss on Zepbound (tirzepatide) based on SURMOUNT clinical trial data
Medical Disclaimer: This tool provides general educational estimates. Always consult your prescribing physician or healthcare provider before making medication changes or interpreting results from population-based models.
Frequently Asked Questions
In SURMOUNT-1 (N=2,539), the 15 mg dose produced 22.5% average weight loss at 72 weeks. The 10 mg dose: 19.5%, 5 mg dose: 15%.
Same drug (tirzepatide) by Eli Lilly. Zepbound is FDA-approved for weight management; Mounjaro for type 2 diabetes. Dosing and mechanism are identical.
Zepbound (tirzepatide) targets GIP + GLP-1; Wegovy (semaglutide) targets GLP-1 only. Zepbound produced up to 22.5% loss vs 14.9% for Wegovy.
Most notice weight loss within 4-8 weeks. Most rapid loss occurs between weeks 12-36 during dose escalation.
Coverage varies. Many commercial plans cover anti-obesity medications. Eli Lilly offers a savings card for eligible patients.
Yes. Projections are from SURMOUNT-1 (Jastreboff et al., NEJM 2022, N=2,539).
Sources
- Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216. (SURMOUNT-1) Link
- Garvey WT, et al. Tirzepatide for obesity in people with type 2 diabetes (SURMOUNT-2). Lancet. 2023. Link
- Aronne LJ, et al. Continued Treatment With Tirzepatide (SURMOUNT-4). JAMA. 2024. Link
- Eli Lilly. Zepbound (tirzepatide) Prescribing Information. FDA.gov. Link
Methodology
This calculator projects weight loss using dose-specific outcomes from SURMOUNT-1 (N=2,539). Base weight loss: 15% (5mg), 19.5% (10mg), 22.5% (15mg) at 72 weeks. Zepbound contains the same drug as Mounjaro (tirzepatide). Non-linear logarithmic scaling with activity adjustments.
Zepbound (tirzepatide) is the same drug as Mounjaro, FDA-approved for weight management. SURMOUNT-1: 15mg = 22.5%, 10mg = 19.5%, 5mg = 15% weight loss at 72 weeks.
What else do you want to know?
Ask Pulse anything.